158 related articles for article (PubMed ID: 27610595)
1. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC.
Plattel WJ; Alsada ZN; van Imhoff GW; Diepstra A; van den Berg A; Visser L
Br J Haematol; 2016 Dec; 175(5):868-875. PubMed ID: 27610595
[TBL] [Abstract][Full Text] [Related]
2. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
Hsi ED; Li H; Nixon AB; Schöder H; Bartlett NL; LeBlanc M; Smith S; Kahl BS; Leonard JP; Evens AM; Scott DW; Rimsza LM; Friedberg JW
Blood; 2019 Apr; 133(16):1762-1765. PubMed ID: 30723079
[TBL] [Abstract][Full Text] [Related]
4. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
5. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.
Cuccaro A; Annunziata S; Cupelli E; Martini M; Calcagni ML; Rufini V; Giachelia M; Bartolomei F; Galli E; D'Alò F; Voso MT; Leone G; Giordano A; Larocca LM; Hohaus S
Cancer Med; 2016 Mar; 5(3):398-406. PubMed ID: 26758564
[TBL] [Abstract][Full Text] [Related]
6. Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.
Viviani S; Mazzocchi A; Pavoni C; Taverna F; Rossi A; Patti C; Romano A; Trentin L; Sorasio R; Guidetti A; Gottardi D; Tarella C; Cimminiello M; Zanotti R; Farina L; Ferreri AJM; Galbiati M; Corradini P; Gianni AM; Gallamini A; Rambaldi A
Hematol Oncol; 2020 Oct; 38(4):501-508. PubMed ID: 32602970
[TBL] [Abstract][Full Text] [Related]
7. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.
Sauer M; Plütschow A; Jachimowicz RD; Kleefisch D; Reiners KS; Ponader S; Engert A; von Strandmann EP
Am J Hematol; 2013 Feb; 88(2):113-5. PubMed ID: 23225085
[TBL] [Abstract][Full Text] [Related]
8. Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study.
Zijtregtop EAM; Diez C; Zwaan CM; Veening MA; Beishuizen A; Meyer-Wentrup FAG
Br J Haematol; 2023 Jan; 200(1):70-78. PubMed ID: 36128637
[TBL] [Abstract][Full Text] [Related]
9. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
Greisen SR; Møller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B
Clin Exp Rheumatol; 2015; 33(4):498-502. PubMed ID: 25962601
[TBL] [Abstract][Full Text] [Related]
10. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma.
Farina L; Rezzonico F; Spina F; Dodero A; Mazzocchi A; Crippa F; Alessi A; Dalto S; Viviani S; Corradini P
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1982-8. PubMed ID: 25240818
[TBL] [Abstract][Full Text] [Related]
11. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.
Plattel WJ; van den Berg A; Visser L; van der Graaf AM; Pruim J; Vos H; Hepkema B; Diepstra A; van Imhoff GW
Haematologica; 2012 Mar; 97(3):410-5. PubMed ID: 22058214
[TBL] [Abstract][Full Text] [Related]
12. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
13. Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.
Levin LI; Breen EC; Birmann BM; Batista JL; Magpantay LI; Li Y; Ambinder RF; Mueller NE; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1114-1123. PubMed ID: 28341757
[No Abstract] [Full Text] [Related]
14. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma.
Nadali G; Vinante F; Stein H; Todeschini G; Tecchio C; Morosato L; Chilosi M; Menestrina F; Kinney MC; Greer JP
J Clin Oncol; 1995 Jun; 13(6):1355-60. PubMed ID: 7751879
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
[TBL] [Abstract][Full Text] [Related]
17. Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis.
Greisen SR; Moller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Jørgensen A; Hvid M; Deleuran B
Clin Exp Rheumatol; 2011; 29(4):689-92. PubMed ID: 21813065
[TBL] [Abstract][Full Text] [Related]
18. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
[TBL] [Abstract][Full Text] [Related]
19. Development of an Electrochemical CCL17/TARC Biosensor toward Rapid Triage and Monitoring of Classic Hodgkin Lymphoma.
Rinaldi C; Corrigan DK; Dennany L; Jarrett RF; Lake A; Baker MJ
ACS Sens; 2021 Sep; 6(9):3262-3272. PubMed ID: 34478275
[TBL] [Abstract][Full Text] [Related]
20. CD30 ligand in lymphoma patients with CD30+ tumors.
Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]